{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-000584","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2024-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.640610+00:00","generated_at":"2026-06-07T04:40:14.607978+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"VYNE Therapeutics appoints Christine Borowski, Ph.D., to board of directors effective Jan 1, 2024","bullets":["Appointed Dr. Christine Borowski as Class II director, effective Jan 1, 2024, for term until 2026 annual meeting.","Dr. Borowski is Vice President at Access Bio and was appointed per prior agreement from Nov 2023 private placement.","Received option to purchase 40,000 shares at $2.33/share, vesting annually over 3 years.","Will receive standard annual cash retainer of $40,000, payable quarterly, plus annual option awards."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-000584","json":"https://secwatch.observer/filing/0001104659-24-000584.json","markdown":"https://secwatch.observer/filing/0001104659-24-000584.md","text":"https://secwatch.observer/filing/0001104659-24-000584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465924000584/0001104659-24-000584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465924000584/tm2333851d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:40:14.607978+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6df0403846","claim":"Christine Borowski was appointed as Director at VYNE Therapeutics Inc..","evidence_excerpt":"On December 29, 2023, the Board appointed Dr. Christine Borowski to serve as a Class II director of the Company, effective as of January 1, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465924000584/0001104659-24-000584-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}